Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Overweight, Obesity, Hypertension, Prehy...
Phase Not Applicable
Enrollment 5000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The Fit2Play prospective cohort study examines the effects of a park-based youth physical activity afterschool program on youth participant fitness and mental health outcomes. Duke will perform a secondary analysis of the data collected as part of the Fit2Play prospective cohort study run by Miami-Dade County Parks and Recreation.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Fit2Play curriculum — Fit2Play is a daily after-school park-based program (Monday-Friday, 2 PM-6 PM) that comprises (1) 60 minutes of physical activity that incorporates multiple sports (soccer, kickball, flag football) and activities from Sports, Play and Active Recreation for Kids (SPARK), a play- and evidenced-based, outcome-oriented, structured, active recreation program for children with a focus on developing and improving motor skills, movement knowledge, social and personal skills; and (2) 20-30 minutes of nutrition education lessons 1-2 times per week that incorporate EmpowerMe4Life, a health and wellness curriculum aligned to the National Health Education Standards for fifth grade and grounded in the American Heart Association's scientific recommendations in promoting heart-healthy lifestyles. Miami-Dade Parks and Recreation is the sponsor of the Fit2Play prospective cohort study. Duke is conducting a secondary data analysis on data collected as part of the Fit2Play study.

Primary Outcomes

  • Change in Weight (Baseline, 12-72 MONTHS)
  • Change in Height (Baseline, 12-72 MONTHS)
  • Change in Waist-to-Hip Circumference (Baseline, 12-72 MONTHS)
  • Change in Pulse (Baseline, 12-72 MONTHS)
  • Change in Blood Pressure (Baseline, 12-72 MONTHS)
  • Change in PACER score (Baseline, 12-72 MONTHS)
  • Change in sit-and-reach test (Baseline, 12-72 MONTHS)
  • Change in number of push-ups (Baseline, 12-72 MONTHS)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-05-07
Completion: 2027-05-17
Eligibility
Age: 6 Years – 14 Years
Sex: ALL
Volunteers: true
Enrollment: 5000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Duke University
Collaborators: Miami-Dade County Parks and Recreation, The Children's Trust, Miami FL
Principal Investigators:
  • Emily D'Agostino, DPH, MS, MEd, MA (PRINCIPAL_INVESTIGATOR) - Duke University
Contact Information
Study Contact:
Emily M D'Agostino, DPH, MS, MEd, MA
+1 919 668 8540
emily.m.dagostino@duke.edu
Interventions
  • Other: Fit2Play curriculum — Fit2Play is a daily after-school park-based program (Monday-Friday, 2 PM-6 PM) that comprises (1) 60 minutes of physical activity that incorporates multiple sports (soccer, kickball, flag football) and activities from Sports, Play and Active Recreation for Kids (SPARK), a play- and evidenced-based, outcome-oriented, structured, active recreation program for children with a focus on developing and improving motor skills, movement knowledge, social and personal skills; and (2) 20-30 minutes of nutrition education lessons 1-2 times per week that incorporate EmpowerMe4Life, a health and wellness curriculum aligned to the National Health Education Standards for fifth grade and grounded in the American Heart Association's scientific recommendations in promoting heart-healthy lifestyles. Miami-Dade Parks and Recreation is the sponsor of the Fit2Play prospective cohort study. Duke is conducting a secondary data analysis on data collected as part of the Fit2Play study.
Study Locations (1 sites)
Miami-Dade County Parks, Recreation and Open Spaces Department, Miami, Florida 33128 United States
Eligibility Criteria
Inclusion Criteria: * All participants enrolled in the Miami-Dade Fit2Play study will be included in this secondary analysis Exclusion Criteria: * Anyone not enrolled in the Miami-Dade Fit2Play study will be excluded from this secondary analysis
Conditions Ischemic Heart Disease (IHD), Anxiety, D...
Phase NA
Enrollment 30
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this feasibility study is to assess if the personalised online psychological intervention MY-CHOICE is acceptable to adults with ischemic heart disease and anxiety or depression. It will also examine the reasons for drop-out. The main questions the study aims to answer are: How many participants complete the intervention and what are the reasons for drop-out. And what are the pre-post change scores on anxiety and depression. Participants will: Complete the MY-CHOICE intervention consisting of 6-12 weeks with online modules on various topics based on individual needs in combination with video- or telephone calls with a therapist (psychologist or a trained master student in Psychology) on a need-to basis. Answer a set of questionnaires pre and post intervention. Participate in a brief interview post intervention.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Online psychological therapy — Online psychological treatment of anxiety and depression for patients with ischemic heart disease tailored to individual needs. The treatment includes access to an online treatment platform offering psychological content and written communication with the therapist and telephone-video conversations with the therapist. The intervention is tailored to meet the patients´ individual needs.

Primary Outcomes

  • Drop-out rate (From enrollment to end of treatment i.e., from 0 to 13 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-04
Completion: 2026-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Southern Denmark
Collaborators: Aarhus University Hospital Skejby, Aalborg University Hospital, Zealand University Hospital
Contact Information
Study Contact:
Pia Behrndtz, Head nurse
+45 21 53 13 49
pib@rn.dk
Aalborg University Hospital, Department of Cardiology
Bent Raungaard, MD
Aalborg University Hospital, Department of Cardiology
Helle L Kanstrup, MD
+45 78 45 20 20
Helle.kanstrup@rm.dk
Aarhus University Hospital, Department of Cardiology
Interventions
  • Other: Online psychological therapy — Online psychological treatment of anxiety and depression for patients with ischemic heart disease tailored to individual needs. The treatment includes access to an online treatment platform offering psychological content and written communication with the therapist and telephone-video conversations with the therapist. The intervention is tailored to meet the patients´ individual needs.
Study Locations (3 sites)
Aalborg University Hospital, Department of Cardiology, Aalborg, 9000 Denmark
Aarhus University Hospital, Department of Cardiology, Aarhus, 8200 Denmark
Zealand University Hospital, Roskilde, Department of Cardiology, Roskilde, 4000 Denmark
Eligibility Criteria
Inclusion Criteria: * ischemic heart disease (diagnostic codes I20-I25), * referred for CR with a positive screen for depression and/or anxiety with the Hospital Anxiety and Depression Scale (HADS ≥ 8) * access to and ability to use a computer or tablet * proficient in the Danish language Exclusion Criteria: * Severe psychiatric disorder (i.e., borderline disorder, schizophrenia or bipolar disorder) that requires psychiatric care * severe cognitive difficulties (e.g., severe brain damage, mental retardation, or dementia) that will prevent patients from participating * endorsement of suicidal ideation with suicidal thoughts (purpose designed questions) that cannot be handled in the intervention * participation in other intervention studies focused (unless they are clinical studies) * seeing a psychologist or mental health professional for the treatment of anxiety and depression * not being able or willing to spend 3-4 hours on the intervention each week * experiencing significant life stressors that hinder adherence to the MY-CHOICE treatment
Conditions Psychological Stress, Sleep Disturbance,...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This decentralized, single-arm study evaluates the effects of 90 days of daily Neuralli Mood supplementation on perceived stress, sleep disturbance, mood, anxiety, depressive symptoms, happiness, and occupational burnout in adults experiencing stress or occasional sleep disruption. Participants serve as their own controls, completing validated self-report measures before beginning supplementation and again after the 90-day intervention, with safety and adherence check-ins during the study.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: Neuralli Mood — Two acid-resistant capsules taken once daily for 90 days. Each daily dose contains 30 billion CFU of L. plantarum PS128 and 20 billion heat-treated cells of L. paracasei PS23. Other ingredients include microcrystalline cellulose, hypromellose, pectin, glycerol, silica, and magnesium stearate.

Primary Outcomes

  • Change in Depression Anxiety and Stress Scales-21 Stress Subscale Score (Baseline before the first dose and end of the 90-day supplementation period)
  • Change in PROMIS Sleep Disturbance Score (Baseline before the first dose and end of the 90-day supplementation period)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-30
Completion: 2027-09-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Efforia, Inc
Collaborators: Bened Life
Principal Investigators:
  • Matthew Amsden (PRINCIPAL_INVESTIGATOR) - Efforia, Inc
Contact Information
Study Contact:
Matthew Amsden
+13232844626
help@efforia.com
Matthew Amsden
help@efforia.com
Efforia - Decentralized United States Study
Matthew Amsden
Efforia - Decentralized United States Study
Interventions
  • Dietary Supplement: Neuralli Mood — Two acid-resistant capsules taken once daily for 90 days. Each daily dose contains 30 billion CFU of L. plantarum PS128 and 20 billion heat-treated cells of L. paracasei PS23. Other ingredients include microcrystalline cellulose, hypromellose, pectin, glycerol, silica, and magnesium stearate.
Study Locations (1 sites)
Efforia - Decentralized United States Study, New York, New York 10003 United States
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older and able to provide informed consent. * Generally healthy adult experiencing stress, occasional sleep disruption, low mood, anxiety symptoms, or work-related burnout. * Willing and able to take two capsules of Neuralli Mood daily for 90 days. * Willing and able to complete electronic baseline, follow-up, adherence, and safety assessments. * Has reliable access to the internet and an email-enabled device. Exclusion Criteria: * Pregnant or nursing. * Known allergy or hypersensitivity to Neuralli Mood, probiotics, or any product ingredient. * Severe or unstable gastrointestinal disease, including a condition for which probiotic use may be inappropriate. * Immunocompromised status or current immunosuppressive therapy. * Severe or unstable mood disorder, acute psychiatric symptoms, or a current risk of harm to self or others. * A clinically significant sleep disorder for which participation or changes in symptoms should be managed by a healthcare professional. * Cognitive impairment or another condition that prevents informed consent or reliable completion of study procedures. * History of a severe allergic reaction when the investigator determines probiotic use may present an unacceptable risk. * Use of a medication or presence of a medical condition for which a healthcare professional advises against probiotic supplementation. * Any other circumstance that, in the investigator's judgment, makes participation inappropriate or unsafe.
Conditions Major Depressive Disorder (MDD), Neuroim...
Phase NA
Enrollment 120
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to validate the therapeutic efficacy and safety of bright light therapy (BLT) in ameliorating cognitive impairment (CI) in major depressive disorder (MDD), characterize the functional and structural features of the hippocampus (HPC)-dorsolateral prefrontal cortex (dlPFC) neural circuitry in MDD participants with CI and examine the mediating effect of the HPC-dlPFC neural circuit on CI induced by BLT treatment in MDD participants. MDD participants will be required to only receive selective serotonin reuptake inhibitors (SSRIs) as monotherapy for at least four weeks, or medication-free status before enrollment. Eligible participants will be randomly assigned to the experimental group and the control group. The experimental group will receive the intervention of BLT, and the control group will receive the intervention of dim red light (DRL). The intervention will last for four weeks, 6 days per week, with 40 minutes each day between 7 am and 10 am. The MDD participants will be followed once in the end of each week during the 4-week intervention and in the end of the 4th week after intervention. Demographic information will be collected at baseline; cognitive function will be evaluated at baseline, weeks 2, 4, and 8 after intervention beginning; and other symptoms such as depression, anxiety and sleep were assessed at baseline, weeks 1, 2, 3, 4, and 8 after intervention beginning. Moreover, structural and functional MRI scans will be made at baseline and post-intervention. During the intervention, MDD participants will be required to keep a record of daily light exposure duration and complete the daily sleep diary as well.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: BLT — Using a hybrid white light box with independent intellectual property rights, with an intensity of 10000lux and a main wavelength of 476.4nm
  • Device: DRL — Using a dim red light box as the placebo, with an intensity of \<100lux and a main wavelength of 690.4nm

Primary Outcomes

  • Symbol Coding (SC) (screen, baseline, weeks2, 4, and 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-10
Completion: 2028-12-31
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Peking University Sixth Hospital
Principal Investigators:
  • Xiaozhen Lv, Ph.D (PRINCIPAL_INVESTIGATOR) - Peking University Sixth Hospital
Contact Information
Study Contact:
Xiaozhen Lv, Ph.D
+8601062723705
lxz120300@163.com
Xiaozhen Lv, Ph.D
+8601062723705
lxz120300@163.com
Peking University Sixth Hospital
Jun Yuan
337559650@qq.com
Yan'an Third People's Hospital
Interventions
  • Device: BLT — Using a hybrid white light box with independent intellectual property rights, with an intensity of 10000lux and a main wavelength of 476.4nm
  • Device: DRL — Using a dim red light box as the placebo, with an intensity of \<100lux and a main wavelength of 690.4nm
Study Locations (2 sites)
Peking University Sixth Hospital, Beijing, Beijing Municipality 100191 China
Yan'an Third People's Hospital, Yanan, Shanxi China
Eligibility Criteria
The inclusion and exclusion criteria for MDD patients. 1、Inclusion Criteria: 1. MDD diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-Ⅳ), first episode or recurrence, confirmed by an experienced psychiatrist using the Mini International Neuropsychiatric Interview. 2. Age between 18 and 60 years; and gender no-limited; 3. The severity of MDD symptoms must be ≥14 scores on the HAMD-17; 4. With CI currently, defined as a total score of \<70 on the SC; 5. A SSRI monotherapy at stable dosages for at least 4 weeks; or medication-free status; 6. Education level above primary school, able to understand and cooperate in completing the study procedures; 7. Voluntarily participating in this study and sign the informed consent before enrollment. 2、Exclusion Criteria: 1. Current or past diagnosis of any disorder other than MDD according to DSM-Ⅳ criteria; 2. The scores on the Young Mania Rating Scale (YMRS) are\>8; 3. The participants who have undergone other intervention in addition to SSRIs whinin the past 6 months or now, or who plan to do that in 1 month; 4. The participants with strong self-blame, self-harm, or suicidal risks (the HAMD-17 suicide item score of ≥3); 5. The participants with severe physical illnesses, including heart failure, renal failure, severe liver dysfunction, hyperthyroidism, or hypothyroidism; Or a history of severe brain trauma or organic brain pathology (e.g., intracerebral hemorrhage, large-area cerebral infarction, encephalitis, epilepsy), as well as neurological diseases; 6. The participants with any degree of retinal pathology, including retinal dystrophy, age-related macular degeneration, diabetic retinopathy, cataracts, glaucoma, or other ocular diseases; 7. The participants with photosensitive conditions, such as systemic lupus erythematosus, porphyria, chronic photodermatitis, solar urticaria, or those currently receiving medications that may increase photosensitivity (e.g., phenothiazines, antimalarials, propranolol, hypericin, stimulants, or chronic treatment with nonsteroidal anti-inflammatory drugs); 8. Pregnant or lactating women; 9. The participants with contraindications to MRI, such as the presence of non-MRI-safe metallic implants or claustrophobia; 10. The participants deem unsuitable for inclusion in this study by the investigator for other reasons. Withdrawal and Termination Criteria: 1. The participants meet one of the exclusion criteria above after enrollment; 2. When the participants' treatment regimen need change; 3. The participants who fail to cooperate or voluntarily withdraw from the study; 4. Due to severe adverse events, the patients are unable to tolerate phototherapy; 5. The participants who fail to adhere to the study protocol intervention for three consecutive days or for a cumulative duration exceeding seven days; 6. Cancellation of the study. The inclusion and exclusion criteria for Health controls 1\. Inclusion criteria 1. Age between 18 and 60 years; and gender no-limited; 2. Without CI currently, defined as a total score of ≤ 70 on the SC; 3. Education level above primary school, able to understand and cooperate in completing the study procedures; 4. Voluntarily participating in this study and sign the informed consent before enrollment. 2.Exclusion criteria 1. Current or past diagnosis of any psychiatric disorders, or history of substance/drug abuse or dependence; 2. Current or past diagnosis of severe somatic diseases, such as heart failure, renal failure, severe liver dysfunction, or hyperthyroidism/hypothyroidism; 3. History of severe traumatic brain injury or organic brain lesions; 4. Pregnant or lactating women; 5. The participants with contraindications to MRI, such as the presence of non-MRI-safe metallic implants or claustrophobia. 6. The participants deem unsuitable for inclusion in this study by the investigator for other reasons.
Conditions Major Depressive Disorder, Borderline Pe...
Phase Not Applicable
Enrollment 20000
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

TRIAGE-Psych is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored psychiatry clinical trials.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Other: Survey — Participants will be surveyed on demographics, medical history, and current psychiatric symptoms. Vital signs, urine drug screens, and urine pregnancy tests may be collected.

Primary Outcomes

  • The proportion of participants who are eligible for industry-sponsored clinical trials, as defined as those who go on to screen for a study (Up to 52 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-12-21
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Adams Clinical
Contact Information
Study Contact:
Miriam Evans, PhD
617-744-8542
mevans@adamsclinical.com
Karla Meehan, MA
617-209-3469
kmeehan@adamsclinical.com
Adams Clinical, Boston
Dyanna Domilici, MD
Adams Clinical, Boston
Interventions
  • Other: Survey — Participants will be surveyed on demographics, medical history, and current psychiatric symptoms. Vital signs, urine drug screens, and urine pregnancy tests may be collected.
Study Locations (6 sites)
Adams Clinical, Boston, Boston, Massachusetts 02116 United States
Adams Clinical, Watertown, Watertown, Massachusetts 02472 United States
Adams Clinical, Harlem, New York, New York 10029 United States
Adams Clinical, Bronx, The Bronx, New York 10461 United States
Adams Clinical, Philadelphia, Philadelphia, Pennsylvania 19104 United States
Adams Clinical, Dallas, DeSoto, Texas 75115 United States
Eligibility Criteria
Inclusion Criteria: * Participant or Legally Authorized Representative has signed an ICF prior to study-specific procedures being performed. * Participant is at least 18 years old. Exclusion Criteria: * Participant is pregnant, breast-feeding, or planning to become pregnant. * History of a clinically significant illness which in the investigator's opinion may impact participant safety or the ability to analyze study results. * Participant represents an acute suicidal risk, as defined as a "yes" response to ideation on C-SSRS questions 4 or 5, or answer "yes" to behavior questions within 90 days of screening. * Moderate or severe substance use disorder within 90 days prior to screen, according to DSM-5 criteria that in the investigator's opinion could pose undue risk to the participant. * Any condition that in the investigator's opinion makes a participant unsuitable for the study. * Currently employed by Adams Clinical or a first-degree relative of an employee.
Conditions Hypertension, Cardiovascular Diseases, V...
Phase Not Applicable
Enrollment 1000
Locations 46 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication. This system is comprised of a catheter, cable, balloon, and generator and has received FDA approval in the United States. Information collected in this study will be analyzed to better understand the long-term safety and effectiveness of treatment with the Paradise System for patients with high blood pressure.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Device: Paradise Ultrasound Renal Denervation Treatment — The Paradise Ultrasound Renal Denervation System (Paradise Ultrasound RDN) is an FDA-approved catheter-based system to treat hypertension by ablating the nerves around the renal arteries, disrupting the overactive sympathetic nerves that can cause high blood pressure. The Paradise procedure uses ultrasound energy to calm the nerves near the kidneys to help lower blood pressure. Treatment is usually done in an outpatient setting and typically takes about an hour to perform. As a part of the treatment, a small flexible tube (catheter) is guided into the blood vessels near the kidneys and 7 seconds of ultrasound energy is applied 2-3 times. Both sides are treated and then the catheter is removed, leaving nothing behind. After the procedure, some people go home the same day or some stay overnight.

Primary Outcomes

  • Co-Primary Endpoint #1: Group Mean BP reduction (Baseline to 3-months post-procedure)
  • Co-Primary Endpoint #2: Subject Responder (Baseline to 3-months post-procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-06-28
Completion: 2031-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: ReCor Medical, Inc.
Contact Information
Study Contact:
Helen Reeve-Stoffer, PhD
+1 650-912-9032
hreeve-stoffer@recormedical.com
Liz Sheehan
Liz.Sheehan@recormedical.com
Christine Ma
562-826-8000
Christine.Agas@va.gov
Tibor Rubin VA Medical Center
Interventions
  • Device: Paradise Ultrasound Renal Denervation Treatment — The Paradise Ultrasound Renal Denervation System (Paradise Ultrasound RDN) is an FDA-approved catheter-based system to treat hypertension by ablating the nerves around the renal arteries, disrupting the overactive sympathetic nerves that can cause high blood pressure. The Paradise procedure uses ultrasound energy to calm the nerves near the kidneys to help lower blood pressure. Treatment is usually done in an outpatient setting and typically takes about an hour to perform. As a part of the treatment, a small flexible tube (catheter) is guided into the blood vessels near the kidneys and 7 seconds of ultrasound energy is applied 2-3 times. Both sides are treated and then the catheter is removed, leaving nothing behind. After the procedure, some people go home the same day or some stay overnight.
Study Locations (46 sites)
Tibor Rubin VA Medical Center, Long Beach, California 90822 United States
Cedars-Sinai Medical Center, Los Angeles, California 90048 United States
Sutter Institute for Medical Research, Sacramento, California 95816 United States
UC Davis Medical Center, Sacramento, California 95817 United States
Pacific Heart Institute, Santa Monica, California 90404 United States
Rocky Mountain Regional VAMC, Aurora, Colorado 80045 United States
Medical Center of the Rockies, Loveland, Colorado 80538 United States
Bridgeport Hosptial, Bridgeport, Connecticut 06610 United States
The Cardiac & Vascular Institute, Gainesville, Florida 32605 United States
University of Miami Health System, Miami, Florida 33136 United States
Eligibility Criteria
Inclusion Criteria: * Signed and dated study informed consent * Documented history of hypertension * Documented history of prior or current antihypertensive medication(s) * Baseline seated office systolic BP at screening ≥ 140 mmHg * Mean pre-procedure home systolic BP of ≥ 135 mmHg * Estimated glomerular filtration rate (eGFR) of ≥30 mL/min/m2 RADIANCE CAP patients must provide signed and dated informed consent for inclusion in long-term follow-up. No other criteria are required for inclusion. Exclusion Criteria: Patients who meet the following will be excluded from participation: * Subject under the age of 18 years old at the time of consent * Subject is pregnant prior to index procedure\^ \^ If a treated subject becomes pregnant after ultrasound RDN procedure, the subject will be followed for outcomes. The ultrasound RDN procedure will be performed according to the IFU for the Paradise System and per the site's standard of care for interventional Procedures.
Conditions Malignant Hypertension
Phase Not Applicable
Enrollment 1200
Locations 37 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This registry aims to provide the first prospective, multicentric database of patients with malignant hypertension. It will allow to assess modern epidemiology of the disease, diversity of current management and care pathway, to deepen our pathophysiological knowledges, to modernize the definition of this form of hypertension and its diagnostic criteria. The network that will emerge will finally lead to the opportunity of setting up therapeutic trials and establishing recommendations based on solid scientific evidence.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • prognosis (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-09-20
Completion: 2034-09-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier de PAU
Contact Information
Study Contact:
Sandra JOST TURILLOT
04 50 63 65 22
sjostturrillot@ch-annecygenevois.fr
CH d'Annecy
Adeline Marie LACRAZ
05 59 44 38 64
alacraz@ch-cotebasque.fr
CH de la côte Basque
Marilucy LOPEZ SUBLET
01 48 95 53 91
marilucy.lopez-sublet@aphp.fr
Avicenne APHP
Interventions
N/A
Study Locations (37 sites)
CH d'Annecy, Annecy, France
CH de la côte Basque, Bayonne, 64109 France
Avicenne APHP, Bobigny, 93009 France
CHU - Hôpital St André, Bordeaux, 33000 France
CH de Chalon sur Saone, Chalon-sur-Saône, France
CH Métropole, Chambéry, 73011 France
CHU de Clermont FERRAND, Clermont-Ferrand, France
Hôpital Henri Mondor, Créteil, France
CH de Dinard, Dinard, 35800 France
CHU Michallon, Grenoble, 38043 France
Eligibility Criteria
Inclusion Criteria: * Malignant hypertension according to the classic definition (Severe hypertension, above 180/110 associated with severe hypertensive retinopathy) * Severe hypertension (above 180/110) associated with acute damage of 3 target organ due to high blood pressure Exclusion Criteria: * Age \< 18 years old * Patients who cannot freely give their consent, or patients who refuse to participate * Dialysis
Conditions Pulmonary Arterial Hypertension
Phase PHASE1
Enrollment 72
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if empagliflozin works to treat patients with pulmonary arterial hypertension. It will also learn about the safety of empagliflozin. The main questions it aims to answer are: Based on standard treatment, does empagliflozin reduce pulmonary artery pressure and improve cardiac function in patients with pulmonary arterial hypertension? What medical problems do participants have when taking empagliflozin? Researchers will compare empagliflozin to a placebo (a look-alike substance that contains no drug) to see if empagliflozin works to treat patients with pulmonary arterial hypertension. Participants will: Take empagliflozin or a placebo every day for 12 weeks Visit the clinic once every 4 weeks for checkups and tests Keep a diary of their symptoms and the drug taking situation

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: empagliflozin in treatment pulmonary aerterial hypertension — On the basis of background treatment, the experimental group was given 10 mg of empagliflozin tablets orally once a day for 12 weeks.
  • Drug: placebo in treatment pulmonary aerterial hypertension — On the basis of background treatment, the control group was given 10 mg of placebo tablets orally once a day for 12 weeks.

Primary Outcomes

  • 6-minute walking distance (From enrollment to the end of treatment at 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-10-20
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 72 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: China National Center for Cardiovascular Diseases
Collaborators: The Second Hospital of Shandong University, The First People's Hospital of Changzhou
Contact Information
Study Contact:
Tingting Guo, M.D
+86 18610094559
18610094559@163.com
Tingting Guo, M.D
+86 18610094559
18610094559@163.com
Fuwai Hospital, Chinese Academy of Medical Sciences
Lu Hua, M.D
Fuwai Hospital, Chinese Academy of Medical Sciences
Interventions
  • Drug: empagliflozin in treatment pulmonary aerterial hypertension — On the basis of background treatment, the experimental group was given 10 mg of empagliflozin tablets orally once a day for 12 weeks.
  • Drug: placebo in treatment pulmonary aerterial hypertension — On the basis of background treatment, the control group was given 10 mg of placebo tablets orally once a day for 12 weeks.
Study Locations (1 sites)
Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality 100037 China
Eligibility Criteria
Inclusion Criteria: 1. At least 18 years old. 2. Sign the informed consent form. 3. Subjects who are willing and able to comply with the requirements of prescribed visits, treatment plans, laboratory examinations and other research procedures. 4. PAH with symptoms was initially diagnosed and belonged to one of the following subgroups: A. Idiopathic pulmonary hypertension (IPAH); B. hereditary pulmonary hypertension (HPAH); C drug or toxin-induced PAH, based on previous exposure to drugs, chemicals or toxins, such as fenfluramine derivatives, other appetite suppressants, toxic rapeseed oil or L- tryptophan. D. PAH is accompanied by: A) connective tissue disease B) Congenital systemic-pulmonary shunt (surgical correction must be performed at least one year before screening, and there is no or no clinically insignificant systemic-pulmonary shunt \[1.0≤ lung-systemic blood flow ratio (QP/QS)≤1.5\]), according to the opinion of the researcher. 5. Received right heart catheterization (RHC) at the time of screening or within 5 years before screening (if RHC is not performed, it will be performed during screening), which is consistent with the diagnosis of PAH and meets all the following criteria: A. mean pulmonary artery pressure (papm) \&gt; 20mmhg (at rest) B pulmonary arteriole wedge pressure (PAWP)≤15 mmHg (if reliable PAWP data cannot be obtained, left ventricular end diastolic pressure \[LVEDP\]≤15 mmHg). C pulmonary vascular resistance (PVR) \&gt; 2.00 wood units (\&gt; 160 dynes/sec/cm5). 6. There are symptoms of WHO/NYHA FC Grade II or III. 7. Stable PAH targeted background oral therapy. Subjects received endothelin receptor antagonist (ERA) and/or phosphodiesterase inhibitor type 5 (PDE5-I) or soluble guanylate cyclase (sGC) agonist. Stability was defined as no change in dose or regimen within 30 days before baseline and during the duration of the study. 8. 6-minute walking distance (6 MWD) ≥ 150m. 9. If the subject is taking concomitant drugs that can affect PAH (for example, calcium channel blockers, digoxin or L- arginine supplements), the dose must be kept stable for at least 30 days before the baseline visit and throughout the study. 10. If there is the possibility of pregnancy, both male and female subjects should agree to use a highly effective contraceptive method during the whole study period (from informed consent to the end of follow-up). Exclusion Criteria: * 1\) Subjects shall not have the following three or more risk factors for left ventricular dysfunction: Body mass index (BMI)≥30 kg/m2 History of systemic hypertension There is any of the following evidence to prove the history of major coronary artery disease: A coronary angiographic evidence of a history of myocardial infarction or percutaneous coronary intervention or coronary artery disease (at least one coronary artery stenosis \&gt; 50%); B. Positive results of exercise provocation test and image evidence; C. previous coronary artery bypass surgery; D. stable angina pectoris; 2) Pulmonary function tests (PFTs) conducted within 180 days before or during the screening showed mild or above lung diseases. Subjects who meet any of the following criteria will be excluded: A. forced expiratory volume in the first second (FEV1)\&lt;60% (expected value); or B total lung volume (TLC) \&lt; 60% of the estimated value. 3) The evidence of thromboembolic disease is confirmed by lung ventilation/perfusion (V/Q) scanning or local standard diagnosis and treatment evaluation at the time of diagnosis or after diagnosis of PAH. 4\) Severe chronic liver disease (i.e. Child-pugh grade C), portal hypertension, cirrhosis or complications of cirrhosis/portal hypertension (e.g., history of varicose bleeding, history of hepatic encephalopathy). 5\) Confirm the active infection of hepatitis B virus (HBV) or hepatitis C virus (HCV). 6\) Subjects whose alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level is more than or equal to 3 times the normal upper limit value (ULN) or whose total bilirubin is more than or equal to 2 times ULN at the time of screening. 7\) Chronic renal insufficiency at screening, which is defined as serum creatinine \&gt; 2.5 mg/dL or requiring dialysis support. 8\) Hemoglobin concentration \&lt; 9 g/dL during screening. 9) diabetes. 10) cardiac function grade IV (NYHA classification) 11) The subject has been treated with IV or SC prostacyclin pathway drugs (for example, epoprostol, triprostinil or iloprost) at any time before baseline (allowed to be used in pulmonary vasodilation test). 12\) The subject has pulmonary vein occlusion disease. 13) Diagnosed and/or treated with malignant tumor within 5 years before screening, but excluding localized non-metastatic basal cell carcinoma or squamous cell carcinoma of the skin, or radical resection of cervical carcinoma in situ. 14\) At the time of screening, there was a history of alcohol or drug abuse within 6 months. 15\) Start the exercise-based cardiopulmonary rehabilitation program within 90 days of the screening period and/or during the study period. 16\) Participated in other interventional clinical studies within 30 days before screening. It is allowed to participate in registered or observational studies at the same time, as long as the subjects meet all other selection criteria and comply with all research process requirements. 17\) Any reason (for example, any past or intermittent diseases) that the respondent thinks may increase the risk of participating in the study or may affect the study analysis and damage the study participation or collaboration, so that the subject cannot participate in the study. 18\) Those who are known to be allergic to Engelgin or any auxiliary materials. 19) According to the researcher\&#39;s judgment, life expectancy is less than 12 months. 20\) Pregnant or lactating women.
Conditions Insomnia, Hypertension
Phase PHASE4
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

Insomnia is a common sleep disorder characterized by difficulty falling asleep, staying asleep, or both, despite appropriate opportunities for getting sleep. Growing evidence has associated insomnia with prevalent and incidence of hypertension. However, the impact of the pharmacologic treatment of insomnia on office blood pressure (BP) and 24-h ambulatory BP monitoring (ABPM) in unclear. Therefore, the aim of this study is to evaluate the impact of eszopiclone, a non-benzodiazepine hypnotic that binds to certain subunits of the gamma-aminobutyric acid type A receptors GABA-A (such as α1, α3, and α5) promoting relaxation and sleep. Eszopiclone is an FDA-approved treatment for insomnia in those who have difficulty falling asleep and for patients with difficulty staying asleep (sleep maintenance).

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Eszopiclone 3 mg — Eszopiclone is an FDA-approved treatment for insomnia in those who have difficulty falling asleep and for patients with difficulty staying asleep (sleep maintenance).
  • Drug: Placebo — Placebo pills identical to the active comparator.

Primary Outcomes

  • Efficacy of insomnia treatment on blood pressure (evaluated by Ambulatory blood pressure monitoring) (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-06-04
Completion: 2026-12-31
Eligibility
Age: 30 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Sao Paulo
Collaborators: Eurofarma Laboratorios S.A.
Principal Investigators:
  • Luciano F. Drager, MD, PhD (STUDY_CHAIR) - University of Sao Paulo Medical School
Contact Information
Study Contact:
LUCIANO F DRAGER, MD, PhD
+5511988027887
luciano.drager@incor.usp.br
Amanda A Brito
+5511976765005
amanda.abrito@hc.fm.usp.br
Academic Research Organization - Heart Institute (InCor)
Interventions
  • Drug: Eszopiclone 3 mg — Eszopiclone is an FDA-approved treatment for insomnia in those who have difficulty falling asleep and for patients with difficulty staying asleep (sleep maintenance).
  • Drug: Placebo — Placebo pills identical to the active comparator.
Study Locations (1 sites)
Academic Research Organization - Heart Institute (InCor), São Paulo, São Paulo 05403900 Brazil
Eligibility Criteria
Inclusion Criteria: * Adults (30 to 75 years-old) * BMI \<40Kg/m2; * Availability to participate * History of HBP under regular treatment (systolic pressure between 130-160 and diastolic pressure between 80-100 mmHg). Exclusion Criteria: * Use of benzodiazepines or "Z" drugs; * Night workers; * History of severe chronic obstructive pulmonary disease (COPD); * Heart failure (ejection fraction \<40% on echocardiogram); * Prior stroke; * Generalized anxiety disorder (GAD-7 \>14 points) and severe depression (Beck); * Severe liver disease; * Alcohol abuse; * Advanced chronic kidney disease 4 or 5 (glomerular filtration rate \<30ml/min/1.73m2); * Patient who is on loop diuretics; * Patient with type 1 diabetes; * Patient with decompensated type 2 diabetes (Glycated hemoglobin \>10%); * Urinuria Incontinence; * Prostatism; * History of active cancer; * Pregnancy; * Complex sleep behaviors, suicidal behavior.
Conditions Idiopathic Pulmonary Arterial Hypertensi...
Phase Not Applicable
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the features of susceptibility and resilience to PAH. This proposal will fundamentally overturn the prevailing understanding of PAH by creating molecularly-driven signatures of susceptibility and resilience, provide novel insight into disease severity, and potentially identify new therapeutic targets. Funding Source - FDA OOPD

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Change in Quality of Life as measured by the emPHasis-10 (Baseline to 32 months)
  • Change in Quality of Life as measured by the Pediatric Quality of Life Inventory Version 4.0 (Baseline to 32 months)
  • Change in meters walked in six-minute walk distance (meters) (Baseline to 32 months)
  • Change in diffusing capacity for carbon monoxide (DLCO) on the Pulmonary Function Test (Baseline to 32 months)
  • Change in Tricuspid Annular Plane Systolic Excursion (TAPSE), expressed in mm. (Baseline to 32 months)
  • Change in Tricuspid Annular Velocity (S'), as assessed by echocardiogram results, expressed in cm/sec (Baseline to 32 months)
  • Change in Estimated Right Ventricle (RV) Systolic Pressure, as assessed by echocardiogram results, expressed in mmHg (Baseline to 32 months)
  • Change in Right Ventricle (RV) Free Wall Longitudinal Strain, as assessed by echocardiogram results, and expressed as percent (%) change in myocardial deformation. (Baseline to 32 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-11-01
Completion: 2026-08-31
Eligibility
Age: 15 Years – 80 Years
Sex: ALL
Volunteers: Not specified
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vanderbilt University Medical Center
Principal Investigators:
  • Evan Brittain, MD (PRINCIPAL_INVESTIGATOR) - Vanderbilt Medical Center
  • Anna Hemnes, MD (PRINCIPAL_INVESTIGATOR) - Vanderbilt Medical Center
  • Eric Austin, MD (PRINCIPAL_INVESTIGATOR) - Vanderbilt Medical Center
Contact Information
Study Contact:
Kelly Burke, RN
(615) 343-4682
kelly.burke@vumc.org
Alisha Lindsey, RT
(615) 343-4682
alisha.lindsey@vumc.org
Kelly Burke, RN
kelly.burke@vumc.org
Vanderbilt University Medical Center
Interventions
N/A
Study Locations (1 sites)
Vanderbilt University Medical Center, Nashville, Tennessee 37232 United States
Eligibility Criteria
Inclusion Criteria: * Children and Adults, aged 15 - 80 * Diagnosed with idiopathic or heritable, pulmonary arterial hypertension (PAH), defined according to standard criteria * Unaffected Mutation Carriers: Healthy participants with a known BMPR2 gene mutation and normal pulmonary pressure and RV function on echo * Healthy Controls: Healthy individuals without cardiopulmonary disease. * WHO functional class I-III * Stable PAH-specific medication regimen for three months prior to enrollment. Subjects with only a single diuretic adjustment in the prior three months will be included. Adjustments in IV prostacyclin for side effect management are allowed. Exclusion Criteria: * Prohibited from normal activity due to wheelchair bound status, bed bound status, reliance on a cane/walker, activity-limiting angina, activity-limiting osteoarthritis, or other condition that limits activity. * Pregnancy * Diagnosis of PAH etiology other than idiopathic, heritable * Functional class IV heart failure * Requirement of \> 2 diuretic adjustment in the prior three months.
Conditions Atrial Hypertension
Phase PHASE3
Enrollment 3000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

Hypertension (HTN) is a leading cause of cardiovascular disease (CVD). Despite existing therapies, patients with HTN still face substantial risks, due to pre-existing and ongoing end-organ damage due, in part, to inadequate blood pressure (BP) control. SGLT2 inhibitors (SGLT2i) are recommended for both type-2 diabetes and heart failure to reduce morbidity and mortality. SGLT2i reduce BP and might also improve outcomes for HTN by reducing end-organ damage through diverse other actions. However, confirmation that SGLT2i are clinically useful for the management of HTN is required to change guidelines and clinical practice.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Factorial Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: SGLT2 — 10 mg
  • Drug: Placebo — 1 tablet

Primary Outcomes

  • Time until first occurrence of (7 Years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-12-10
Completion: 2032-05-30
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 3000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Prof. Dr. med. Ingo Eitel
Principal Investigators:
  • Ingo Eitel, Prof. Dr. (PRINCIPAL_INVESTIGATOR) - Universitätsklinikum Schleswig-Holstein - Campus Lübeck
Contact Information
Study Contact:
Ingo Eitel, Prof. Dr.
045150044542
cvro@uksh.de
Elias Rawish, Dr.
Ingo Eitel, Prof. Dr. med.
Universität zu Lübeck
Interventions
  • Drug: SGLT2 — 10 mg
  • Drug: Placebo — 1 tablet
Study Locations (1 sites)
Universität zu Lübeck, Lübeck, Schleswig-Holstein 23538 Germany
Eligibility Criteria
Inclusion Criteria: 1. Age ≥60 years 2. Systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg in two measurements on different days for newly diagnosed hypertension, or through one measurement at the screening visit for patients with an existing diagnosis of hypertension. 3. A history of at least one CV event (myocardial infarction\* or stroke\*; stable angina or clinical evidence of coronary heart disease; peripheral arterial disease; transient ischemic attack) or The presence of at least one cardiovascular risk factor (current smoking of more than one cigarette per day during at least 1 year; LDL-cholesterol \> 4,0 mmol/l, Age ≥ 75 years, ESC HeartScore \> 15%, BMI \> 32 kg/m2) \*excluding patients with myocardial infarction or stroke within preceding 3 months Exclusion Criteria:- Known secondary cause of hypertension * Myocardial infarction or stroke within the previous 3 months * Symptomatic heart failure (including HFrEF, HFmEF, HFpEF) * History of Diabetes mellitus * History of ketoacidosis * Hepatic impairment (aspartate transaminase \[AST\] or alanine transaminase \[ALT\] \>3x the upper limit of normal \[ULN\]) * eGFR \<25 mL/min/1.73 m2 (CKD-EPICr 2021 formula) at Visit 1 * Receiving therapy with an SGLT2i within 8 weeks prior to randomization or previous intolerance to an SGLT2i * Participation in another clinical study with an investigational product during the last month prior to enrolment * Known allergy or hypersensitivity to SGLT2i * Women who are pregnant, nursing, or who plan to become pregnant while in the trial * Any medical condition - outside the renal and CV disease area - with a life expectancy of less than 2 years based on investigator's clinical judgement * Active malignancy requiring treatment at the time of visit 1 (with the exception of successfully treated basal cell or treated squamous cell carcinoma) * Inability to give informed consent
Conditions Pulmonary Hypertension
Phase Not Applicable
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study seeks to describe the real world initial experience with sotatercept in the treatment of pulmonary hypertension.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • EmPHasis10 Questionnaire (Baseline, Year 1, Year 2, Year 3, Year 4, Year 5, Year 6, Year 7, Year 8, Year 9, Year 10)
  • Number of pulmonary hypertension vasodilator medications taken by a subject (Baseline, Year 10)
  • Number of patients to have a change in dose of prostanoid medications (Baseline, Year 10)
  • Number of patient hospitalizations (Baseline, Year 10)
  • Number of patients to cease therapy sessions (Baseline, Year 10)
  • Number of patients to discontinue prostanoid therapy (Baseline, Year 10)
  • Number of patients with bleeding complications (Baseline, Year 10)
  • Number of patients to develop Skin telangiectasias (Baseline, Year 10)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-20
Completion: 2027-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Robert Frantz, M.D. (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Hayden Halbach, M.B.A.
507-255-2648
Halbach.Hayden@mayo.edu
Louise Durst, R.N.
507-284-1838
Robert Frantz, M.D.
Mayo Clinic
Interventions
N/A
Study Locations (1 sites)
Mayo Clinic, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria: * Adults age 18 or greater who are being treated with sotatercept in the Mayo Pulmonary hypertension clinic. Exclusion Criteria: * Adults lacking capacity to consent